Evidence map›Paper›PMID 34113337›Full record

ArticleFrontiers in immunology2021

Altered Immune Phenotypes and

Priyanka Devi-Marulkar, Carolina Moraes-Cabe, Pascal Campagne, Béatrice Corre, Aida Meghraoui-Kheddar, Vincent Bondet, Alba Llibre, Darragh Duffy, Elisabeth Maillart, Caroline Papeix and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Priyanka Devi-MarulkarCytokine Signaling Unit, Department of Immunology, Institut Pasteur, Paris, France.
Carolina Moraes-CabeCytokine Signaling Unit, Department of Immunology, Institut Pasteur, Paris, France.
Pascal CampagneCenter of Bioinformatics, Biostatistics and Integrative Biology, Institut Pasteur, Paris, France.
Béatrice CorreCytokine Signaling Unit, Department of Immunology, Institut Pasteur, Paris, France.
Aida Meghraoui-KheddarCytokine Signaling Unit, Department of Immunology, Institut Pasteur, Paris, France.
Vincent BondetTranslational Immunology Laboratory, Department of Immunology, Institut Pasteur, Paris, France.
Alba LlibreTranslational Immunology Laboratory, Department of Immunology, Institut Pasteur, Paris, France.
Darragh DuffyTranslational Immunology Laboratory, Department of Immunology, Institut Pasteur, Paris, France.
Elisabeth MaillartDepartment of Neurology, Pitié-Salpêtrière Hospital, Paris, France.
Caroline PapeixDepartment of Neurology, Pitié-Salpêtrière Hospital, Paris, France.
Sandra PellegriniCytokine Signaling Unit, Department of Immunology, Institut Pasteur, Paris, France.
Frédérique MichelCytokine Signaling Unit, Department of Immunology, Institut Pasteur, Paris, France.
Institut Pasteur · FRInserm · FRPitié-Salpêtrière Hospital · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Interferon beta (IFN Aim: To determine a combination of cellular and molecular blood signatures associated with the efficacy of IFN Methods: The immune status of 40 RRMS patients, 15 of whom were untreated and 25 that received IFN Results: Clinical responders and non-responders displayed similar plasma levels of IFN

Indexed as

Genetic VariationAdultCase-Control StudiesCD4-Positive T-LymphocytesFemaleHLA-DQ beta-ChainsHumansImmunologic FactorsInterferon beta-1aInterferon Regulatory FactorsMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingPhenotypeTreatment FailureYoung AdultHLA-DQB1 antigenHLA-DQ beta-ChainsImmunologic FactorsInterferon beta-1aInterferon Regulatory Factorsblood biomarkersHLA class II genesimmune phenotypesinterferon-stimulated genesmultiple sclerosisT cellstype I interferon

Identifiers

PMID34113337
PMCPMC8185344
OpenAlexW3165803532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.